PACE-CME

Careful implementation of PCSK9 inhibitors in clinical practice

Careful implementation of PCSK inhibitors in clinical practice
RestartResume
10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)
  • Overview

    CSI Rome Terje Pedersen defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.

  • Educational information

    In the Cardiovascular Scene Investigation (CSI) series, young clinicians with an investigative mindset interview experts about the context and meaning of the results they just presented at the ESC congress.

    The series is aimed to explore the background and practical implications of recent scientific developments, like those discussed in the session on PCSK9 inhibitors in the Gladiators Arena at the ESC Congress 2016, with speakers in this session.

  • Disclosures

    Terje Rolf Pedersen - Professor Emeritus - Department of Endocrinology, Morbid Obesity and Preventive Medicine, UiO Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway

    Lotte Koopal and Gijs Berkelmans - UMC Utrecht, The Netherlands

    The speakers did not receive financial compensation for participating in these interviews

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free